Across TCGA pan-cancer cohorts, IGHV3-21 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IGHV3-21 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IGHV3-21 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV3-21 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where IGHV3-21 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.456	0.850	<.001	40	view →
HNSC	OS	Quartile	III,IV	0.514	0.883	.003	15	view →
PDAC	OS	Tertile	All	0.809	0.122	.024	13	view →
CCRCC	DFS	Median	All	1.000	0.607	.026	7	view →
GBM	OS	Tertile	All	1.000	0.856	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IGHV3-21 tumor-vs-normal RNA expression · all IGHV3-21 data types